Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability
Your insurance must provide some coverage for Ozempic
The abdomen is usually the safest site for lean users because it retains subcutaneous fat even at lower overall body fat percentages
Logos and endorsements presented without sources are a credibility shortcut and a red flag for any patient checking sources before signing up
Pancreatitis: Inflammation in the pancreas, or pancreatitis, can cause belly pain, upset stomach, vomiting and weight loss
